title: [Treatment guidelines for the idiopathic nephrotic syndrome in children].
authors.forename: Norishige
authors.initials: N
authors.lastname: Yoshikawa
authors.forename: Masataka
authors.initials: M
authors.lastname: Honda
authors.forename: Kouji
authors.initials: K
authors.lastname: Sekine
authors.forename: Kouichi
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Issei
authors.initials: I
authors.lastname: Iijima
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ootomo
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikeda
authors.forename: Naohiro
authors.initials: N
authors.lastname: Wada
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Mayumi
authors.initials: M
authors.lastname: Sako
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D016572:Cyclosporine / Q000008:administration & dosage*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008775:Methylprednisolone / Q000008:administration & dosage; D009404:Nephrotic Syndrome / Q000145:classification / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*; D020551:Pulse Therapy, Drug; D012008:Recurrence; D012263:Ribonucleosides / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone; D008775:Methylprednisolone